Trial record 1 of 2 for:    elan alzheimer agitation
Previous Study | Return to List | Next Study

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborator:
Elan Pharmaceuticals
Information provided by (Responsible Party):
Transition Therapeutics Ireland Limited
ClinicalTrials.gov Identifier:
NCT01735630
First received: November 25, 2012
Last updated: July 8, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2015
  Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)